(Q39914955)

15 September 2017

title

The activity of medroxyprogesterone acetate, an androgenic ligand, in ovarian cancer cell invasion (English)

1 reference

medroxyprogesterone acetate

15 September 2017

main subject

1 reference

ChEBI release 2020-05-28

1 reference

Radhika Gogoi

1

1 reference

15 September 2017

Marek Kudla

series ordinal

2

1 reference

15 September 2017

Orlando Gil

series ordinal

3

1 reference

15 September 2017

David Fishman

series ordinal

4

1 reference

15 September 2017

publication date

1 October 2008

1 reference

15 September 2017

published in

Reproductive Sciences

1 reference

15 September 2017

volume

15

1 reference

15 September 2017

issue

8

1 reference

15 September 2017

page(s)

846-852

1 reference

The human ovarian surface epithelium is an androgen responsive tissue

15 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1933719108323446

Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719108323446

The progestational and androgenic properties of medroxyprogesterone acetate: gene regulatory overlap with dihydrotestosterone in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719108323446

Progesterone metabolism in T47Dco human breast cancer cells--II. Intracellular metabolic path of progesterone and synthetic progestins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719108323446

Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719108323446

Androgen Stimulates Matrix Metalloproteinase-2 Expression in Human Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719108323446

Phase II trial of medroxyprogesterone acetate in advanced ovarian cancer: an EORTC Gynecological Cancer Cooperative Group Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719108323446

Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719108323446

New progestogens: a review of their effects in perimenopausal and postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719108323446

Cloning and expression of a novel, truncated, progesterone receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719108323446

LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719108323446

The tumor microenvironment: key to early detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719108323446

Progestin suppresses matrix metalloproteinase production in endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719108323446

Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1933719108323446

21 January 2018

Identifiers

DOI

10.1177/1933719108323446

1 reference

15 September 2017

1 reference